March 16 | 2024
2CUREX AB (PUBL) PROVIDES AN UPDATE ON ITS FINANCIAL POSITION AND CURRENT OPERATIONS
Read more
February 29 | 2024
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)
Read more
February 22 | 2024
2CUREX PUBLISHES INTERIM REPORT FOR THE FOURTH QUARTER AND FULL YEAR OF 2023 AND FINANCIAL AND STRATEGIC OUTLOOK FOR 2024
Read more
February 12 | 2024
NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)
Read more
January 4 | 2024
2cureX announces changes to the Board of Directors.
Read more
December 29 | 2023
2cureX announces changes to the management
Read more
December 6 | 2023
2cureX Receives Ethical Approval for Groundbreaking HIPEC Clinical Trial
Read more
November 23 | 2023
2cureX publishes interim report for the third quarter of 2023
Read more
November 14 | 2023
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)
Read more
November 10 | 2023
IndiTreat® Image Uploader gets IVD CE-Mark
Read more
October 30 | 2023
2cureX participated in “Knæk Cancer” panel discussion.
Read more
October 26 | 2023
Strategy update: Leapfrogging to the decentralization of IndiTreat® testing through full focus on automation
Read more
October 25 | 2023
NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)
Read more
October 11 | 2023
2cureX advances towards IVD-R compliance by securing a contract with a Notified Body
Read more
October 3 | 2023
2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).
Read more
August 30 | 2023
2cureX launches its first two IndiTreat® products CE-marked under the new IVD Regulation
Read more
August 24 | 2023
2cureX publishes interim report for Q2 2023
Read more
July 5 | 2023
Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)
Read more